This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rakha, E. A. Articles by Ellis, I. O. Search for Related Content PubMed Articles by Rakha, E. A. Articles by Ellis, I. O. Social Bookmarking                            What's this?

Basal-Like Breast Cancer: A Critical Review

Emad A. Rakha, Jorge S. Reis-Filho, Ian O. Ellis

From the Department of Histopathology, Nottingham City Hospital National Health Service (NHS) Trust; Nottingham University, Nottingham; and the Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom

Corresponding author: Ian O. Ellis, FRCPath, Molecular Medical Sciences, University of Nottingham, Department of Histopathology, Nottingham City Hospital NHS Trust, Hucknall Road, Nottingham, NG5 1PB, UK; e-mail: ian.ellis{at}nottingham.ac.uk

Recent gene expression profiling of breast cancer has identified specific subtypes with clinical, biologic, and therapeutic implications. The basal-like group of tumors is characterized by an expression signature similar to that of the basal/myoepithelial cells of the breast and is reported to have transcriptomic characteristics similar to those of tumors arising in BRCA1 germline mutation carriers. They are associated with aggressive behavior and poor prognosis, and typically do not express hormone receptors or HER-2 ("triple-negative" phenotype). Therefore, patients with basal-like cancers are unlikely to benefit from currently available targeted systemic therapy. Although basal-like tumors are characterized by distinctive morphologic, genetic, immunophenotypic, and clinical features, neither an accepted consensus on routine clinical identification and definition of this aggressive subtype of breast cancer nor a way of systematically classifying this complex group of tumors has been described. Different definitions are, therefore, likely to produce variable and contradictory results that may hamper consistent identification and development of treatment strategies for these tumors. In this review, we discuss definition, heterogeneity, morphologic spectrum, relation to BRCA1, and clinical significance of this important class of breast cancer.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S Pintens, P Neven, M Drijkoningen, V Van Belle, P Moerman, M-R Christiaens, A Smeets, H Wildiers, and I V. Bempt Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1 J. Clin. Pathol., July 1, 2009; 62(7): 624 - 628. [Abstract] [Full Text] [PDF]

				D. Raina, R. Ahmad, M. D. Joshi, L. Yin, Z. Wu, T. Kawano, B. Vasir, D. Avigan, S. Kharbanda, and D. Kufe Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells Cancer Res., June 15, 2009; 69(12): 5133 - 5141. [Abstract] [Full Text] [PDF]

				A. Moreno-Aspitia and E. A. Perez Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane Mayo Clin. Proc., June 1, 2009; 84(6): 533 - 545. [Abstract] [Full Text] [PDF]

				M. Hickey, M. Peate, C.M. Saunders, and M. Friedlander Breast cancer in young women and its impact on reproductive function Hum. Reprod. Update, May 1, 2009; 15(3): 323 - 339. [Abstract] [Full Text] [PDF]

				E. Alli, V. B. Sharma, P. Sunderesakumar, and J. M. Ford Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase Cancer Res., April 15, 2009; 69(8): 3589 - 3596. [Abstract] [Full Text] [PDF]

				J. H. Lee, E. L. Rosen, and D. A. Mankoff The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1--Overview, Detection, and Staging J. Nucl. Med., April 1, 2009; 50(4): 569 - 581. [Abstract] [Full Text] [PDF]

				E. A. Rakha, S. E. Elsheikh, M. A. Aleskandarany, H. O. Habashi, A. R. Green, D. G. Powe, M. E. El-Sayed, A. Benhasouna, J.-S. Brunet, L. A. Akslen, et al. Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes Clin. Cancer Res., April 1, 2009; 15(7): 2302 - 2310. [Abstract] [Full Text] [PDF]

				T. Uematsu, M. Kasami, and S. Yuen Triple-Negative Breast Cancer: Correlation between MR Imaging and Pathologic Findings Radiology, March 1, 2009; 250(3): 638 - 647. [Abstract] [Full Text] [PDF]

				B. P. Schneider, E. P. Winer, W. D. Foulkes, J. Garber, C. M. Perou, A. Richardson, G. W. Sledge, and L. A. Carey Triple-Negative Breast Cancer: Risk Factors to Potential Targets Clin. Cancer Res., December 15, 2008; 14(24): 8010 - 8018. [Abstract] [Full Text] [PDF]

				E. Castro and E. de Alava The risk of taking the part by the whole Ann. Onc., November 1, 2008; 19(11): 1975 - 1976. [Full Text] [PDF]

				D. H. Roukos, E. Lykoudis, and T. Liakakos Genomics and Challenges Toward Personalized Breast Cancer Local Control J. Clin. Oncol., September 10, 2008; 26(26): 4360 - 4361. [Full Text] [PDF]